10 Years' experience with the pneumococcal quinolone moxifloxacin

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 6, 2009, Pages 645-668

  Burkhardt, Olaf ^a,b   Welte, Tobias ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Central Clinic Bad Berka   (Germany)

Author keywords

Clinical efficacy; Moxifloxacin; Perspectives; Pharmacodynamics; Pharmacokinetics; Respiratory tract infections; Safety

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFALEXIN; CEFTRIAXONE; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE; SPARFLOXACIN; SULTAMICILLIN; TROVAFLOXACIN; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE;

ABDOMINAL INFECTION; ANAPHYLAXIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTHROPATHY; ASPIRATION PNEUMONIA; BACTERIAL SINUSITIS; BACTERICIDAL ACTIVITY; BIOFILM; BRONCHITIS; CARDIOVASCULAR DISEASE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DIABETIC FOOT; DIARRHEA; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INHIBITION; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR NOSE THROAT DISEASE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HELICOBACTER INFECTION; HOSPITAL INFECTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IN VITRO STUDY; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LOWER RESPIRATORY TRACT INFECTION; LUNG ABSCESS; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE DRUG DOSE; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PELVIC INFLAMMATORY DISEASE; PHARMACODYNAMICS; PHARYNGITIS; PHYSICAL CHEMISTRY; PNEUMONIA; POSTMARKETING SURVEILLANCE; PSEUDOMEMBRANOUS COLITIS; QT PROLONGATION; RESPIRATORY TRACT INFECTION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SKIN ABSCESS; SKIN INFECTION; SOFT TISSUE INFECTION; STRUCTURE ACTIVITY RELATION; TENDINITIS; TORSADE DES POINTES; TREATMENT DURATION; CROSS INFECTION; DRUG EFFECT; MICROBIOLOGY; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE; TIME; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CROSS INFECTION; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS; TREATMENT OUTCOME;

EID: 70350443266     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.46     Document Type: Review

References (177)

1. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'. J. Antimicrob. Chemother. 43(Suppl. B), 1-11 (1999).
2. Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin. Drug Invest. 17(5), 365-387 (1999). (Pubitemid 29253469)
3. Krasemann C, Meyer J, Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin. Infect. Dis. 32(Suppl. 1), S51-S63 (2001). (Pubitemid 32506747)
4. Andriole VT. The quinolones: past, present, and future. Clin. Infect. Dis. 41(Suppl. 2), S113-S119 (2005). • Thorough review of fluoroquinolones.
5. Vogel F, Scholz H, Al-Nawas B et al. Rational use of oral antibiotics. Findings of an expert commission of the Paul Ehrlich Society for Chemotherapy. Med. Monatsschr. Pharm. 25(6), 193-204 (2002).
6. Dalhoff A. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clin. Infect. Dis. 32(Suppl. 1), S16-S22 (2001). (Pubitemid 32506741)
7. Avalox® (Moxifloxacin) Product profile. Bayer Vital, Leverkusen, Germany, Revised May 2005.
8. AVELOX®/AVELOX® I.V. Prescribing information. Bayer Healthcare Pharmaceuticals Inc., Leverkusen, Germany, Revised October 2008.
9. Avelox® 400 mg film-coated tablets. Summary of product characteristics. Bayer Healthcare Pharmaceuticals Inc., Leverkusen, Germany, Revised March 2008.
10. Pestova E, Millichap JJ, Noskin GA, Peterson LR. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J. Antimicrob. Chemother. 45(5), 583-590 (2000). (Pubitemid 30255636)
11. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 33(4), 685-706 (1994).
12. Peterson LR. Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. Clin. Infect. Dis. 33(Suppl. 3), S180-186 (2001). • Modes of action for fluorquinolones in general and moxifloxacin especially, were described in detail. Very important review to understand the pharmacology of fluorquinolones.
13. Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin. Infect. Dis. 32(Suppl. 1), S9-S15 (2001).
14. LaPlante KL, Rybak MJ, Tsuji B, Lodise TP, Kaatz GW. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. Antimicrob. Agents Chemother. 51(4), 1315-1320 (2007). (Pubitemid 46586811)
15. MacGowan AP. Moxifloxacin (BAY 12-8039): a new methoxyquinolone antibacterial. Exp. Opin. Invest. Drugs. 8(2), 181-199 (1999).
16. Jacobs E, Dalhoff A, Korfmann G. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study). Int. J. Antimicrob. Agents 33(1), 52-57 (2009). • Provided extensive in vitro susceptibility data for moxifloxacin.
17. Gottlieb T, Collignon PJ, Robson JM, Pearson JC, Bell JM. Prevalence of antimicrobial resistances in Streptococcus pneumoniae in Australia, 2005: report from the Australian Group on Antimicrobial Resistance. Commun. Dis. Intell. 32(2), 242-249 (2008).
18. Farrell DJ, Felmingham D, Shackcloth J et al. Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. J. Antimicrob. Chemother. 62(Suppl. 2), ii87-ii95 (2008).
19. Morrissey I, Maher K, Williams L, Shackcloth J, Felmingham D, Reynolds R. Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007. J. Antimicrob. Chemother. 62(Suppl. 2), ii97-ii103 (2008). (Pubitemid 35049519)
20. Bébéar CM, de Barbeyrac B, Pereyre S, Renaudin H, Clerc M, Bébéar C. Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin. Microbiol. Infect. 14(8), 801-805 (2008).
21. Hsueh PR, Yang JC, King CHR. In vitro activity of nemonoxacin against Helicobacter pylori. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA, 25-28 October 2008 (Poster C2-3931).
22. Edmiston CE, Krepel CJ, Seabrook GR et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob. Agents Chemother. 48(3), 1012-1016 (2004).
23. Edmiston CE Jr, Krepel CJ, Kehl KS et al. Comparative in vitro antimicrobial activity of a novel quinolone garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. J. Antimicrob. Chemother. 56(5), 872-878 (2005).
24. Limeres J, Tomás I, Àlvarez M, Diz P. Empirical antimicrobial therapy for odontogenic infections. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 100(3), 263-264 (2005). (Pubitemid 41191334)
25. Burkhardt O, Borner K, Stass H et al. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand. J. Infect. Dis. 34(12), 898-903 (2002). (Pubitemid 36193135)
26. Klugman KP, Capper T. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin. J. Antimicrob. Chemother. 40(6), 797-802 (1997). (Pubitemid 28022143)
27. Boswell FJ, Andrews JM, Wise R, Dalhoff A. Bactericidal properties of moxifloxacin and post-antibiotic effect. J. Antimicrob. Chemother. 43(Suppl. B), 43-49 (1999). (Pubitemid 29231793)
28. MacGowan AP. Pharmacodynamics of moxifloxacin. Moxifloxacin in Practice 2, 5-15 (1999).
29. Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42(6), 410-425 (1996). • Excellent paper on moxifloxacin's in vitro antibacterial activity.
30. Wiedemann B. In vitro pharmacodynamics of moxifloxacin against respiratory tract pathogens. Moxifloxacin in Practice 2, 17-25 (1999).
31. Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. 47(6), 811-818 (2001).
32. Rubinstein E, Diamantstein L, Yoseph G et al. The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and E. coli. Clin. Microbiol. Infect. 6(12), 678-681 (2000). (Pubitemid 34966095)
33. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin. Infect. Dis. 32(Suppl. 1), S39-46 (2001). •• Describes the current knowledge regarding the role of pharmacocinetics and pharmacodynamics to guide antibiotic treatment in clinical practice.
34. Wispelwey B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin. Infect. Dis. 41(Suppl. 2), S127-S135 (2005). (Pubitemid 40962483)
35. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45(2), 433-438 (2001). (Pubitemid 32105277)
36. Ballow C, Lettieri J, Agrawal V, Liu P, Stass H, Sullivan JT. Absolute bioavailability of moxifloxacin. Clin. Ther. 21(3), 513-522 (1999).
37. Stass H, Kubitza D, Unger S. The effect of food on the oral bioavailability of moxifloxacin in healthy male volunteers. Moxifloxacin in Practice 3, 15-24 (2000).
38. Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents Chemother. 42 (8), 2060-2065 (1998). (Pubitemid 28363093)
39. Stass H, Kubitza D, Schuhly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin. Pharmacokinet. 40(Suppl. 1), 1-9 (2001). (Pubitemid 32295676)
40. Avelox® 400 mg/250 ml solution for infusion. Summary of product characteristics. Bayer Healthcare Pharmaceuticals Inc., Leverkusen, Germany, Revised February 2007.
41. Breilh D, Jougon J, Djabarouti S et al. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. J. Chemother. 15(6), 558-562 (2003). (Pubitemid 38241404)
42. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J. Antimicrob. Chemother. 43(Suppl. 2), 83-90 (1999). (Pubitemid 29231798)
43. Sullivan JT, Woodruff M, Lettieri J et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob. Agents Chemother. 43(11), 2793-2797 (1999). (Pubitemid 29519568)
44. Wise R, Andrews JM, Marshall G, Hartman G. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob. Agents Chemother. 43(6), 1508-1510 (1999). (Pubitemid 29259357)
45. Joukhadar C, Stass H, Müller-Zellenberg U et al. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob. Agents Chemother. 47(10), 3099-3103 (2003). (Pubitemid 37229563)
46. Capitano B, Mattoes HM, Shore E et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 125(3), 965-973 (2004). (Pubitemid 38367287)
47. Leone M, Albanèse J, Sampol-Manos E et al. Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia. Antimicrob. Agents Chemother. 48(2), 638-640 (2004). (Pubitemid 38141733)
48. Stass H, Joukhadar C, Möller JG, Müller M. Concentrations of moxifloxacin at the focus of infection of patients suffering from erysipelas after a 400-mg single dose. Presented at: 12th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Milan, Italy 24-27 April 2002 (Abstract P0178).
49. Siefert HM, Domdey-Bett A, Henninger K, Hucke F, Kohlsdorfer C, Stass HH. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J. Antimicrob. Chemother. 43(Suppl. B), 69-76 (1999). (Pubitemid 29231796)
50. Simon N, Sampol E, Albanese J et al. Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. Clin. Pharmacol. Ther. 74(4), 353-363 (2003). • Excellent pharmacokinetic study. (Pubitemid 37222856)
51. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 44(6), 835-838 (1999). (Pubitemid 32684726)
52. Pascual A, García I, Ballesta S, Perea EJ. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. Antimicrob. Agents Chemother. 43(1), 12-15 (1999). (Pubitemid 29069191)
53. Grayo S, Join-Lambert O, Desroches MC, Le Monnier A. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob. Agents Chemother. 52(5), 1697-1702 (2008). (Pubitemid 351614662)
54. Weiner M, Burman W, Luo CC et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob. Agents Chemother. 51(8), 2861-2866 (2007). (Pubitemid 47206223)
55. Dooley K, Flexner C, Hackman J et al. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob. Agents Chemother. 52(11), 4037-4042 (2008).
56. Stass H, Kubitza D, Wensing G. Pooled analysis of pharmacokinetics, safety and tolerability of single oral 400 mg moxifloxacin doses in patients with mild and moderate liver cirrhosis. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, Canada, 17-20 September 2000 (Abstract P2269).
57. Stass H, Kubitza D, Halabi A, Delesen H. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br. J. Clin. Pharmacol. 53(3), 232-237 (2002). (Pubitemid 34226965)
58. Ittner KP, Roth G, Gruber M, Pawlik M, Tager K. Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro. J. Antimicrob. Chemother. 56(29), 360-364 (2005). (Pubitemid 41158526)
59. Fuhrmann V, Schenk P, Jaeger W, Ahmed S, Thalhammer F. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J. Antimicrob. Chemother. 54(4), 780-784 (2004). (Pubitemid 39386731)
60. Czock D, Hüsig-Linde C, Langhoff A et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin. J. Am. Soc. Nephrol. 1(6), 1263-1268 (2006).
61. Barth J, Jäger D, Mundkowski R, Drewelow B, Welte T, Burkhardt O. Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment. J. Antimicrob. Chemother. 62(3), 575-578 (2008). • First ertapenem pharmacokinetic study in patients with liver cirrhosis.
62. Bonora S, Mondo A, Trentini L, Calcagno A, Lucchini A, Di Perri G. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. J. Infect. 57(1), 78-81 (2008).
63. Rustomjee R, Lienhardt C, Kanyok T et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12(2), 128-138 (2008). (Pubitemid 351212403)
64. Codecasa LR, Ferrara G, Ferrarese M et al. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir. Med. 100(9), 1566-1572 (2006). (Pubitemid 44109116)
65. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J. Chemother. 15(1), 66-70 (2003). (Pubitemid 36355891)
66. Al-Nawas B, Walter C, Morbach T et al. Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: a pilot study. Eur. J. Clin. Microbiol. Infect. Dis. 28(1), 75-82 (2009).
67. Cachovan G, Giersdorf I, Hallier O et al. Efficacy and tolerability of moxifloxacin versus clindamycin in the treatment of odontogenic abscesses and inflammatory infiltrates (MOCLI Study). Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona, Spain, 19-22 April 2008 (Abstract O83).
68. Miehlke S, Schneider-Brachert W, Kirsch C et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 13(1), 69-74 (2008).
69. Bago P, Vcev A, Tomic M, Rozankovic M, Marusić M, Bago J. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien. Klin. Wochenschr. 119(11-12), 372-378 (2007). (Pubitemid 47087507)
70. Torres A, Muir JF, Corris P et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-aquired pneumonia. Eur. Respir. J. 21(1), 135-143 (2003). (Pubitemid 36150313)
71. Welte T, Burkhardt O, Marre R, Suttorp N for the CAPNETZ Study Group. CAPNETZ: Data on clinical efficacy of antibiotic therapy and mortality of CAP in Germany. Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona, Spain, 19-22 April 2008 (Abstract P844).
72. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 119(1), 185-195 (2001). (Pubitemid 32150566)
73. Iannini PB, Paladino JA, Lavin B, Singer ME, Schentag JJ. A case series of macrolide treatment failures in community acquired pneumonia. J. Chemother. 19(5), 536-545 (2007). (Pubitemid 350177965)
74. Fogarty C, Grossman C, Williams J, Haverstock D, Church D. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect. Med. 16(11), 748-763 (1999).
75. Finch R, Schürmann D, Collins O et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob. Agents Chemother. 46(6), 1746-1754 (2002). • Recent clinical trial of moxifloxacin efficacy for community-acquired pneumonia (CAP). (Pubitemid 34535192)
76. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Intern. Med. 159(21), 2562-2572 (1999).
77. Welte T, Petermann W, Schuermann D, Bauer TT, Reimnitz P; MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin. Infect. Dis. 41(12), 1697-1705 (2005). •• Recent clinical trial of moxifloxacin efficacy for CAP. (Pubitemid 41759850)
78. Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH. Community-acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin. Infect. Dis. 42(1), 73-81 (2006). •• Recent comparative clinical trial of moxifloxacin versus levofloxacin efficacy for CAP in the elderly. (Pubitemid 41832083)
79. Torres A, Garau J, Arvis P et al.; MOTIV (Moxifloxacin Treatment IV) Study Group. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: The MOTIV study - a randomized clinical trial. Clin. Infect. Dis. 46(10), 1499-1509 (2008). •• Recent clinical trial of moxifloxacin efficacy for CAP. (Pubitemid 351706729)
80. Lode H, Grossman C, Choudhri S et al. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. Respir. Med. 97(10), 1134-1142 (2003). (Pubitemid 37185117)
81. Wenisch C, Krause R, Széll M, Laferl H. Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment. Infection 34(4), 190-195 (2006). (Pubitemid 44214502)
82. Fogarty C, Torres A, Choudhri S, Haverstock D, Herrington J, Ambler J. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia. Int. J. Clin. Pract. 59(11), 1253-1259 (2005). (Pubitemid 43904492)
83. Hoeffken G, Talan D, Larsen LS et al. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens. Eur. J. Clin. Microbiol. Infect. Dis. 23(10), 772-775 (2004). (Pubitemid 39517852)
84. Garau J, Breilmann J, Arvis P, Haverstock D, Choudhri SH. Moxifloxacin efficacy versus community-acquired pneumonia (CAP) caused by Legionella: a pooled analysis. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, USA, 27-30 September 2006 (Abstract L-1449).
85. Höffken G, Barth J, Rubinstein E, Beckmann H; HAP study group. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia. Infection 35(6), 414-420 (2007).
86. Ott SR, Allewelt M, Lorenz J, Reimnitz P, Lode H; The German Lung Abscess Study Group. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 36(1), 23-30 (2008).
87. Polenakovik H, Burdette SD, Polenakovik S. Moxifloxacin is efficacious for treatment of community-acquired lung abscesses in adults. Clin. Infect. Dis. 41(7), 764-765 (2005). (Pubitemid 41170373)
88. Miravitlles M, Molina J, Brosa M. Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis. Arch. Bronconeumol. 43(1), 22-28 (2007). (Pubitemid 46232753)
89. Anzueto A, Miravitlles M, Ewig S, Legnani D, Landen H, Stauch K. Greatest international anti-infective trial (GIANT): comparison of interim results from Europe and Asia. Presented at: ATS 2007 International Conference. San Francisco, USA (2007) (Poster A49).
90. Wilson R, Allegra L, Huchon G et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 125(3), 953-964 (2004). •• Recent clinical trial of moxifloxacin efficacy for acute exacerbations of chronic bronchitis. (Pubitemid 38367286)
91. Wilson R, Kubin R, Ballin I et al. Five day moxifloxacin therapy compared with 7-day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 44(4), 501-513 (1999). (Pubitemid 29490621)
92. Hautamaki D, Bruya T, Kureishi A, Warner J, Church D. Short-course (5-day) moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitis. Todays Ther. Trends 19, 117-136 (2001). (Pubitemid 32487883)
93. Chodosh S, DeAbate CA, Haverstock D et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir. Med. 94(1), 18-27 (2000). (Pubitemid 30113846)
94. DeAbate CA, Mathew CP, Warner JH, Heyd A, Church D. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir. Med. 94(11), 1029-1037 (2000).
95. Schaberg T, Ballin I, Huchon G, Bassaris H, Hampel B, Reimnitz P. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J. Int. Med. Res. 29(4), 314-328 (2001). (Pubitemid 32926987)
96. Kreis SR, Herrera N, Golzar N, Fuller HD, Heyd A. A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. J. Clin. Outcomes Manage. 7(12), 33-37 (2000). (Pubitemid 33223533)
97. Grassi C, Casali L, Curti E et al. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J. Chemother. 14(6), 597-608 (2002). (Pubitemid 36135415)
98. Li-McLeod J, Perfetto EM. Workplace costs associated with acute exacerbations of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. Manag. Care Interface 14(2), 52-59 (2001).
99. Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone. Expert Opin. Pharmacother. 9(10), 1755-1772 (2008).
100. Petitpretz P, Choné C, Trémolières F; Investigator Study Group. Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval. Int. J. Antimicrob. Agents 30(1), 52-59 (2007). (Pubitemid 46874906)
101. Gehanno P, Berche P, Perrin A. Moxifloxacin in the treatment of acute maxillary sinusitis after first-line treatment failure and acute sinusitis with high risk of complications. J. Int. Med. Res. 31(5), 434-447 (2003). (Pubitemid 37321953)
102. Arrieta JR, Galgano AS, Sakano E et al.; Moxifloxacin in Acute Sinusitis Study (MASS) Latin American Study Group. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis. Am. J. Otolaryngol. 28(2), 78-82 (2007).
103. Baz MN, Jannetti W, Villanueva C et al. The efficacy and tolerability of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis. Todays Ther. Trends 17(4), 303-319 (1999). (Pubitemid 30003020)
104. Burke T, Villanueva C, Mariano H et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group. Clin. Ther. 21(10), 1664-1677 (1999).
105. Klossek JM, Siegert R, Nikolaidis P, Arvis P, Leberre MA. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. J. Laryngol. Otol. 117(1), 43-51 (2003). (Pubitemid 36084237)
106. Rakkar S, Roberts K, Towe BF, Flores SM, Heyd A. Moxifloxacin versus amoxycillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience. Int. J. Clin. Pract. 55(5), 309-315 (2001). (Pubitemid 32605792)
107. Siegert R, Gehanno P, Nikolaidis P et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir. Med. 94(4), 337-344 (2000). (Pubitemid 30323568)
108. Ariza H, Rojas R, Johnson P et al. Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis. BMC Ear Nose Throat Disord. 6, 8 (2006). 109 Johnson P, Cihon C, Herrington J, Choudhri S. Efficacy and tolerability of moxifloxacin in the treatment of acute bacterial sinusitis caused by penicillin-resistant Streptococcus pneumoniae: a pooled analysis. Clin. Ther. 26(2), 224-231 (2004). (Pubitemid 44064112)
109. Keating KN, Friedman HS, Perfetto EM. Moxifloxacin versus levofloxacin for treatment of acute rhinusinusitis: a retrospective database analysis of treatment duration, outcomes, and charges. Curr. Med. Res. Opin. 22(2), 327-333 (2006).
110. Guay DRP. Moxifloxacin in the treatment of skin and skin structure infections. Ther. Clin. Risk Manag. 2(4), 417-434 (2006).
111. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int. J. Antimicrob. Agents 26(5), 357-365 (2005). (Pubitemid 41483465)
112. Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J, Amábile-Cuevas CF, Arvis P, Bogner J. Sequential IV/PO moxifloxacin (MXF) as effective as co-amoxiclav (AMC) against complicated skin and skin structure infections (cSSSIs). Presented at: 20th European Congress on Surgical Infections. Frankfurt, Germany (2007) (Poster P4).
113. Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J. Antimicrob. Chemother. 60(2), 370-376 (2007). (Pubitemid 47243888)
114. Bogner JR, Arvis P, Choudhri S, Pertel P, Brielmann JM. Clinical and bacteriological efficacy of sequential intravenous (IV) to oral (PO) moxifloxacin in hospitalised patients with major skin abscesses. Presented at: 20th European Congress on Surgical Infections. Frankfurt, Germany (2007) (Poster P30).
115. Weiß G, Reimnitz P, Hampel B, Muehlhofer E, Lippert H; The Aida Study Group. Moxifloxacin for the treatment of patients with complicated intraabdominal infections. J. Chemother. 21 (2), 170-180 (2009)
116. Malangoni MA, Song J, Herrington J, Choudhri S, Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann. Surg. 244(2), 204-211 (2006). (Pubitemid 44305534)
117. Ross JDC, Cronjé HS, Paszkowski T et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sex. Transm. Infect. 82(6), 446-451 (2006). (Pubitemid 46025184)
118. Heystek MJ, Tellarini M, Schmitz H, Krasemann C. Efficacy and safety of moxifloxacin vs ciprofloxacin plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease. Int. J. STD AIDS (2009) (In Press).
119. Meisel C, Prass K, Braun J et al. Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke. Stroke 35(1), 2-6 (2004). (Pubitemid 38057579)
120. Harms H, Prass K, Meisel C et al. Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PLoS ONE 3(5), e2158 (2008). (Pubitemid 352025150)
121. Elies W, Landen H, Stauch K. Efficacy and tolerability of moxifloxacin in patients with sinusitis treated in general practice: results of a post-marketing surveillance study. Clin. Drug Investig. 24(8), 431-439 (2004). (Pubitemid 39128009)
122. Koch H, Landen H, Stauch K. Once-daily moxifloxacin therapy for community-acquired pneumonia in general practice: evidence from a post-marketing surveillance study of 1467 patients. Clin. Drug Investig. 24(8), 441-448 (2004). (Pubitemid 39128009)
123. Koch H, Landen H, Stauch K. Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany. Clin. Drug Investig. 24(8), 449-455 (2004). (Pubitemid 39128011)
124. Barth J, Stauch K, Landen H. Efficacy and tolerability of sequential intravenous/oral moxifloxacin therapy in pneumonia. Clin. Drug Invest. 25(11), 691-700 (2005).
125. Faich GA, Morganroth J, Whitehouse AB et al. Clinical experience with moxifloxacin in patients with respiratory tract infections. Ann. Pharmacother. 38(5), 749-754 (2004). (Pubitemid 38509046)
126. Landen H, Bauer T. Efficacy, onset of action and tolerability of moxifloxacin in patients with community-acquired pneumonia. Clin. Drug Invest. 21(12), 801-811 (2001).
127. Schaberg T, Möller M, File T, Stauch K, Landen H. Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice. Clin. Drug Investig. 26(12), 733-744 (2006). (Pubitemid 44901702)
128. Bogner JR, Wild T, Landen H. Avelox® routine treatment of complicated skin and skin structure infections (ARTOS) - first interim results of this international non-interventional study. Presented at: 20th European Congress on Surgical Infections. Frankfurt, Germany (2007) (Poster P6).
129. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect. Dis. 3(6), 359-371 (2003). • Immunomodulatory effects of fluoroquinolones are a matter of debate. This manuscript summarizes the currently available data and provides possible scenarios for studies in the future.
130. Hall IH, Schwab UE, Ward ES, Ives TJ. Effects of moxifloxacin in zymogen A or S. aureus stimulated human THP-1 monocytes on the inflammatory process and the spread of infection. Life Sci. 73(21), 2675-2685 (2003).
131. Shalit I, Kletter Y, Halperin D et al. Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia. Eur. J. Haematol. 66(5), 287-296 (2001). (Pubitemid 32552162)
132. Weiss T, Shalit I, Blau H et al. Antiinflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob. Agents Chemother. 48(6), 1974-1982 (2004).
133. Choi JH, Song MJ, Kim SH et al. Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 47(12), 3704-3707 (2003).
134. Dalhoff K, Demedts S, Strassburg A, Drömann D. Lokale Inflammation bei Infektionen der unteren Atemwege (LRTI) unter Antibiotikatherapie. Infection 35(Suppl. 1), 13-14 (2007).
135. Trautmann M, Scheibe C, Möricke A. Influence of moxifloxacin on endotoxin release of Escherichia coli. Presented at: 12th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Milan, Italy (2002) (Poster 1066).
136. Ulrich M, Albers C, Möller JG et al. Moxfloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against Streptococcus pneumoniae in vitro when administered up to 6 hours after challenge. Antimicrob. Agents Chemother. 49(12), 5119-5122 (2005). (Pubitemid 41778929)
137. Hammerschmitt S, Berlinghoff R, Kuhn H, Wirtz H. Moxifloxacin verbessert die Toleranz alveolärer Typ-2-Zellen gegenüber mechanischer Belastung. Presented at: 49 Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP). Lübeck, Germany (2008) (Poster P139).
138. Rotondetto S, Spiteri M, Thomson C. In vitro effects of moxifloxacin in human respiratory ciliary kinetics. Presented at: 3rd European Congress of Chemotherapy (ECC). Madrid, Spain (2000) (Poster 176).
139. Gamarra F, Stauss E, Huber RM. Einfluss von Moxifloxacin auf die mukoziliäre Clearance. Klinik & Forschung 10(Suppl. 1), 28 (2004).
140. Roveta S, Schito AM, Marchese A, Schito GC. Activity of moxifloxacin on biofilms produced in vitro by bacterial pathogens involved in acute exacerbations of chronic bronchitis. Int. J. Antimicrob. Agents 30(5), 415-421 (2007). (Pubitemid 47498968)
141. Kalteis T, Beckmann J, Schröder HJ et al. Treatment of implant-associated infections with moxifloxacin: an animal study. Int. J. Antimicrob. Agents 27(5), 444-448 (2006).
142. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin. Ther. 26(7), 940-950 (2004). (Pubitemid 39141801)
143. Iannini PB, Kubin R, Reiter C. Over 10 million patient uses: an update on the safety profile of oral moxifloxacin. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Diego, USA (2002) (Poster L-374).
144. Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf. 28(5), 443-452 (2005).
145. Morganroth J, DiMarco JP, Anzueto A, Niederman MS, Choudhri S; CAPRIE Study Group. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 128(5), 3398-3406 (2005). (Pubitemid 41698670)
146. Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin. Infect. Dis. 41(Suppl. 2), S144-S157 (2005). • Review of special clinical interest.
147. Gavin JR 3rd, Kubin R, Choudhri S et al. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Drug Saf. 27(9), 671-686 (2004).
148. Johannes CB, Ziyadeh N, Seeger JD, Tucker E, Reiter C, Faich G. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. Drug Saf. 30(8), 705-713 (2007). (Pubitemid 47295830)
149. Dhalla IA, Mamdani MM, Simor AE, Kopp A, Rochon PA, Juurlink DN. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antimicrob. Agents Chemother. 50(9), 3216-3219 (2006). (Pubitemid 44396444)
150. Beaulieu M, Thirion DJG, Williamson D, Pichette G. Clostridium difficile-associated diarrhea outbreaks: The name of the game is isolation and cleaning. Clin. Infect. Dis. 42(5), 725 (2006). (Pubitemid 43271390)
151. Polson JE. Hepatotoxicity due to antibiotics. Clin. Liver Dis. 11(3), 549-561 (2007).
152. Kothe H, Bauer T, Marre R, Suttorp N, Welte T, Dalhoff K; Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Competence Network for Community-Acquired Pneumonia study group. Eur. Respir. J. 32(1), 139-146 (2008).
153. Leal del Rosal P, Fabian G, Vick-Fragaso R et al. Efficacy and safety of moxifloxacin (MXF) vs. cephalexin (with or without metronidazole) in the treatment of mild to moderate uncomplicated skin and skin structure infections (uSSSI) (Abstract). Proceedings of: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA, 1076, 26-29 September 1999.
154. Leal del Rosal P, Martinez R, Fabian G et al. Efficacy and safety of moxifloxacin vs. cephalexin in the treatment of mild to moderate uncomplicated skin and skin structure infections (USSSI). J. Antimicrob. Chemother. 44(Suppl. A), 493 (1999).
155. Kanellakopoulou K, Pagoulatou A, Stroumpoulis K et al. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. J. Antimicrob. Chemother. 61(6), 1328-1331 (2008). (Pubitemid 351753602)
156. Wagenlehner FME, Kees F, Weidner W, Wagenlehner C, Naber KG. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. Int. J. Antimicrob. Agents. 31(1), 21-26 (2008). (Pubitemid 350236732)
157. Esposito S, Noviello S, D'Errico G et al. Moxifloxacin concentrations in plasma and tonsillar tissue in adult patients. J. Antimicrob. Chemother. 57(4), 789-792 (2006).
158. Gehanno P, Darantière S, Dubreuil C et al. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J. Antimicrob. Chemother. 49(5), 821-826 (2002). (Pubitemid 34537644)
159. Burkhardt O, Derendorf H, Jäger D et al. Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis. Scand. J. Infect. Dis. 38(10), 904-908 (2006). (Pubitemid 44499425)
160. Majcher-Peszynska J, Karrasch K, Saß M et al. Tissue penetration and pharmacokinetics of moxifloxacin in diabetic foot infections: an interim analysis. Presented at: 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Nice, France, 1-4 April 2006 (Abstract P1516).
161. Stass H, Joukhadar C, Möller JG, Müller M. Penetration of moxifloxacin into the infected tissues of patients suffering from diabetic foot infections determined by microdialysis. Presented at: 12th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Milan, Italy, 24-27 April 2002 (Abstract P0179).
162. Malincarne L, Ghebregzabher M, Moretti MV et al. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. J. Antimicrob. Chemother. 57(5), 950-954 (2006).
163. Metallidis S, Charokopos N, Nikolaidis J et al. Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery. Int. J. Antimicrob. Agents 28(5), 428-432 (2006). (Pubitemid 44636183)
164. Gusinde J, Olk A, Schmid O, Freiwald M, Sörgel F, Henning FFF. Die konzentration von moxifloxacin im serum, knochen- und muskelgewebe beim alloarthroplastischen Hüftgelenkersatz nach präoperativer oraler Applikation. Klinik & Forschung 10(Suppl. 1), 44-45 (2004).
165. Müller M, Stass H, Brunner M, Möller JG, Lackner E, Eichler HG. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob. Agents Chemother. 43(10), 2345-2349 (1999). (Pubitemid 29471207)
166. Wirtz M, Kleeff J, Swoboda S. Moxifloxacin penetration into human gastrointestinal tissues. J. Antimicrob. Chemother. 53(5), 875-877 (2004). (Pubitemid 38660296)
167. Rink AD, Stass H, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. Clin. Drug Investig. 28(2), 71-79 (2008).
168. Stass H, Rink AD, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J. Antimicrob. Chemother. 58(3), 693-696 (2006). (Pubitemid 44288143)
169. Metallidis S, Lazaraki G, Tsona A et al. Serum and ascitic fluid concentrations following a single IV dose of 400 mg moxfloxacin. Presented at: 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Nice, France, 1-4 April 2006 (Abstract R1922).
170. Schwab D, Grauer M, Hahn EG, Mühldorfer S. Biliary secretion of moxifloxacin in obstructive cholangitis and the non-obstructed biliary tract. Aliment. Pharmacol. Ther. 22(5), 417-422 (2005). (Pubitemid 41248108)
171. Wacke R, Förster S, Adam U et al. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. J. Antimicrob. Chemother. 58(5), 994-999 (2006).
172. Stass H, Kubitza D, Aydeniz B, Wallwiener D, Halabi A, Gleiter C. Penetration and accumulation of moxifloxacin in uterine tissue. Int. J. Gynaecol. Obstet. 102(2), 132-136 (2008).
173. Wagenlehner FME, Lunz JC, Kees F, Wieland W, Naber KG. Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate. J. Chemother. 18(5), 485-489 (2006). (Pubitemid 44776159)
174. Lott MN, Fuller JJ, Hancock HA et al. Vitreal penetration of oral moxifloxacin in humans. Retina 28(3), 473-476 (2008).
175. Katz E, Larsen LS, Fogarty CM, Hamed K, Song J, Choudhri S. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J. Emerg. Med. 27(4), 395-405 (2004). (Pubitemid 39388679)
176. Parish LC, Routh HB, Miskin B et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int. J. Clin. Pract. 54(8), 497-503 (2000).
177. EMEA. Annex II. The scientific conclusions and the grounds for amendments of the summary of product characteristics and package leaflet. December 2008. http://ec.europa.eu/enterprise/pharmaceuticals/register/refh-others.htm